Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "GLP-1 Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target indication, Geography, Leading Developers and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.
The GLP-1 Market is valued at USD 49.3 billion in 2024 growing at a CAGR of 11.1% during the forecast period 2024-2035.
GLP-1 receptor agonists are a class of medications primarily utilized for managing blood sugar levels / glucose levels in individuals with type 2 diabetes. Further, a few GLP-1 agonists can also help in the treatment of obesity and related heart disease (cardiovascular disease). It is important to mention that, according to a study conducted by Lancet, 42.4% of adult individuals in the US are obese.
Moreover, according to the World Health Organization (WHO), 4 million people die annually due to obesity. In addition, nearly 530 million global adult population suffer from diabetes, with 98% of those having type 2 diabetes and prevalence of diabetes is expected to increase to nearly 1.3 billion by 2050, making it a significant public health concern. It is worth mentioning that, according to the American Diabetes Association, diabetes was the eighth leading cause of death in 2021.
In recent years, there has been a notable shift in consumer lifestyles driven by the growing influence of social media, celebrity endorsements and direct-to-consumer advertising. This has led to a surge in the demand for weight loss and type 2 diabetes treatment solutions, which is likely to spur innovation and market expansion in this domain. In order to address the increasing demand for type 2 diabetes and body weight management drugs, various initiatives have been undertaken by players to develop drugs for treatment of such indications; of these, GLP-1 agonist drugs have emerged as promising option driven by the significant number of positive clinical trial results, along with continuous research and development efforts.
Over the past few years, a number of GLP-1 drugs targeting obesity and type 2 diabetes have received regulatory approvals globally. In 2024, the FDA approved Wegovy, developed by Novo Nordisk, for the treatment of serious heart problems in adults with obesity or overweight. Given the lucrative potential of these drugs, the GLP-1 market, also known as GLP-1 receptor agonist market, has gained significant attention of both private and public investors leading to the substantial market growth during the forecast period.
Research Coverage:
- Elaborate profiles of prominent players developing GLP-1 drugs (shortlisted based on the number of drugs in its pipeline). Each profile features a brief overview of the company (including information on its year of establishment, number of employees, location of headquarters and leadership team), financial information, drug portfolio, recent developments and an informed future outlook.
- A detailed analysis of the partnerships inked between stakeholders in the GLP-1 industry
- An in-depth analysis of the factors that can impact the growth of GLP-1 companies.
- A detailed GLP-1 receptor agonist market forecast analysis in order to estimate the existing market size and future opportunity for GLP-1 companies over the next decade.
- Detailed projections of the current and future revenues from the sales of drugs developed by the leading players, namely Boehringer Ingelheim, Eli Lilly, Novo Nordisk and other players.
Key Topics Covered:
1 BACKGROUND
1.1. Context
1.2. Project Objectives
2 RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.3. Trade Policies
3.2.4. Recession
3.2.5. Inflation
4 EXECUTIVE SUMMARY
5 INTRODUCTION
5.1. Overview of the GLP-1 Drug
5.2. Important Facts in GLP-1 Domain
5.3. Future Perspectives
6 MARKET LANDSCAPE: GLP-1 DRUGS
6.1. GLP-1 Drugs: Market Landscape
6.2. GLP-1 Drugs: Developer Landscape
7 GLP-1 DRUGS: DETAILED COMPANY PROFILES
7.1. Chapter Overview
7.1.1. AstraZeneca
7.1.1.1. Company Overview
7.1.1.2. Pipeline Portfolio
7.1.1.3. Financial Details
7.1.1.4. Recent Developments and Future Outlook
7.1.2. D&D Pharmatech
7.1.3. Eli Lilly
7.1.4. Novo Nordisk
7.1.5. Pfizer
7.1.6. Sanofi
7.1.7. Tonghua Dongbao Pharmaceutical
7.1.8. Vivani
8 GLP-1 DRUGS: BRIEF COMPANY PROFILES
8.1. Chapter Overview
8.1.1. Biolingus
8.1.1.1. Company Overview
8.1.1.2. Pipeline Portfolio
8.1.2. Boehringer Ingelheim
8.1.3. Gmax Biopharm
8.1.4. Hanmi Pharmaceutical
8.1.5. Innogen
8.1.6. PegBio
8.1.7. QL Biopharma
8.1.8. Roche
8.1.9. Sciwind Biosciences
8.1.10. Viking Therapeutics
8.1.11. vTv Therapeutics
8.1.11.1. Company Overview
8.1.11.2. Pipeline Portfolio
9 PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. GLP-1 Market: Partnerships and Collaborations
9.3.6. Analysis by Geography
9.3.6.1. Intercontinental and Intracontinental Deals
9.3.6.2. Local and International Deals
10 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
10.1. Chapter Overview
10.2. Market Drivers
10.3. Market Restraints
10.4. Market Opportunities
10.5. Market Challenges
10.6. Conclusion
11 GLOBAL GLP-1 MARKET
11.1. Assumptions and Methodology
11.2. Global GLP-1 Market, Historical Trends and Forecasted Estimates, till 2035
11.2.1. Scenario Analysis
11.2.1.1. Conservative Scenario
11.2.1.2. Optimistic Scenario
11.2.2. Key Market Segmentations
12 GLP-1 MARKET, BY TYPE OF MOLECULE
12.1. Assumptions and Methodology
12.2. GLP-1 Market: Distribution by Type of Molecule, 2020, 2024 and 2035
12.2.1. GLP-1 Market for Biologics, till 2035
12.2.2. GLP-1 Market for Small Molecules, till 2035
12.3. Data Triangulation and Validation
13 GLP-1 MARKET, BY ACTIVE COMPOUND USED
13.1. Assumptions and Methodology
13.2. GLP-1 Market: Distribution by Active Compound Used, 2020, 2024 and 2035
13.2.1. GLP-1 Market for Dulaglutide, till 2035
13.2.2. GLP-1 Market for Liraglutide, till 2035
13.2.3. GLP-1 Market for Orforglipron, till 2035
13.2.4. GLP-1 Market for Retatrutide, till 2035
13.2.5. GLP-1 Market for Semaglutide, till 2035
13.2.6. GLP-1 Market for Survodutide, till 2035
13.2.7. GLP-1 Market for Tirzepatide, till 2035
13.2.8. GLP-1 Market for Other Active Compounds, till 2035
13.3 Data Triangulation and Validation
14 GLP-1 MARKET, BY TYPE OF GLP-1 AGONIST DURGS
14.1. Assumptions and Methodology
14.2. GLP-1 Market: Distribution by Type (Long,Short Acting) of GLP-1 Agonist Drugs, 2020, 2024 and 2035
14.3. Data Triangulation and Validation
15 GLP-1 MARKET, BY GLP-1 AGONIST
15.1. Assumptions and Methodology
15.2. GLP-1 Market: Distribution by GLP-1 Agonist, 2020, 2024 and 2035
15.3. Data Triangulation and Validation
16 GLP-1 MARKET, BY ROUTE OF ADMINISTRATION
16.1. Assumptions and Methodology
16.2. GLP-1 Market: Distribution by Route of Administration, 2020, 2024 and 2035
16.3. Data Triangulation and Validation
17 GLP-1 MARKET, BY TARGET INDICATION
17.1. Assumptions and Methodology
17.2. GLP-1 Market: Distribution by Target Indication, 2020, 2024 and 2035
17.2.1. GLP-1 Market for Alzheimer's Disease, till 2035
17.2.2. GLP-1 Market for Non-Alcoholic Steatohepatitis, till 2035
17.2.3. GLP-1 Market for Obesity, till 2035
17.2.4. GLP-1 Market for Sleep Apnea, till 2035
17.2.5. GLP-1 Market for Type 2 Diabetes, till 2035
17.3. Data Triangulation and Validation
18 GLP-1 MARKET, BY GEOGRAPHY
18.1. Assumptions and Methodology
18.2. GLP-1 Market: Distribution by Geography, 2020, 2024 and 2035
18.3. Data Triangulation and Validation
19 GLP-1 MARKET, SALES FORECAST OF GLP-1 DRUGS
19.1. Chapter Overview
19.2. Approved GLP-1 Drugs: Sales Forecast
19.2.1. Feisumei (Benaglutide) Sales Forecast
19.2.2. Fu Laimei (Polyethylene Glycol Loxenatide) Sales Forecast
19.2.3. Mounjaro (Tirzepatide) Sales Forecast
19.2.4. Ozempic (Semaglutide Subcutaneous) Sales Forecast
19.2.5. Rybelsus (Semaglutide Oral) Sales Forecast
19.2.6. Saxenda (Liraglutide) Sales Forecast
19.2.7. Trulicity (Dulaglutide) Sales Forecast
19.2.8. Victoza (Liraglutide) Sales Forecast
19.2.9. Wegovy (Semaglutide Subcutaneous) Sales Forecast
19.2.10. XULTOPHY (Insulin Degludec / Liraglutide ) Sales Forecast
19.2.11. Zepbound (Tirzepatide) Sales Forecast
19.3. Phase III GLP-1 Drugs: Sales Forecast
19.3.1. GMA102 / Glutazumab Sales Forecast
19.3.2. JY09 Sales Forecast
19.3.3. LY3298176 / Tirzepatide Sales Forecast
19.3.4. Mazdutide / LY3305677/ IBI-362 Sales Forecast
19.3.5. Orforglipron / LY3502970 Sales Forecast
19.3.6. PB-119 / PEG-exenatide / Polyethylene glycol exenatide Sales Forecast
19.3.7. Retatrutide / LY3437943 Sales Forecast
19.3.8. Semaglutide Oral Sales Forecast
19.3.9. Semaglutide Subcutaneous Sales Forecast
19.3.10. Survodutide / BI 456906 Sales Forecast
19.3.11. XW003 / Ecnoglutide Sales Forecast
19.3.12. YN011-isupaglutide Sales Forecast
20 GLP-1 MARKET, BY LEADING DRUG DEVELOPERS
20.1. Chapter Overview
20.2. GLP-1 Market: Distribution by Leading Drug Developers, 2020 (USD Million)
20.3. GLP-1 Market: Distribution by Leading Drug Developers, 2024 (USD Million)
20.4. GLP-1 Market: Distribution by Leading Drug Developers, 2035 (USD Million)
21 APPENDIX 1: TABULATED DATA
22 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/lnqxty
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
